Iron Metabolism and Iron Chelation in Sickle Cell Disease

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Acta Haematologica

• Publication date

  2009-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000243802PMID 19907155
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications.

  2009cited by this paper
• Iron metabolism in the anemia of chronic disease.

  2009cited by this paper
• Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia

  2009cited by this paper
• Regulation of serum hepcidin levels in sickle cell disease

  2009cited by this paper
• Identification of TWSG 1 as a second novel erythroid regulator of hepcidin expression in murine and human cells

  2009cited by this paper
• Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells.

  2009cited by this paper
• Magnetic resonance detection of kidney iron deposition in sickle cell disease: A marker of chronic hemolysis

  2008cited by this paper
• A Heme Export Protein Is Required for Red Blood Cell Differentiation and Iron Homeostasis

  2008cited by this paper
• Ascorbic acid--important for iron metabolism.

  2008cited by this paper
• Global epidemiology of haemoglobin disorders and derived service indicators.

  2008cited by this paper
• Role of the kidney in iron homeostasis: renal expression of Prohepcidin, Ferroportin, and DMT1 in anemic mice.

  2008cited by this paper
• Patient-Reported Outcomes of Deferasirox (Exjade®, ICL670) versus Deferoxamine in Sickle Cell Disease Patients with Transfusional Hemosiderosis

  2008cited by this paper
• Importance of molecular studies on major blood groups--intercellular adhesion molecule-4, a blood group antigen involved in multiple cellular interactions.

  2008cited by this paper
• Upregulation of neutrophil gelatinase-associated lipocalin, NGAL/Lcn2, in beta-thalassemia patients.

  2008cited by this paper
• Regulation of iron absorption in hemoglobinopathies.

  2008cited by this paper
• Autocrine formation of hepcidin induces iron retention in human monocytes.

  2008cited by this paper
• Iron regulation and erythropoiesis

  2008cited by this paper
• Urinary hepcidin in congenital chronic anemias

  2007cited by this paper
• High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin

  2007cited by this paper
• Liver iron concentrations and urinary hepcidin in beta-thalassemia.

  2007cited by this paper
• Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2/4.

  2007cited by this paper
• A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease

  2007cited by this paper
• Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs).

  2007cited by this paper
• Nature of non-transferrin-bound iron: studies on iron citrate complexes and thalassemic sera

  2007cited by this paper
• GDF15, a Cardioprotective TGF-β Superfamily Protein

  2006cited by this paper
• GDF15, a cardioprotective TGF-beta superfamily protein.

  2006cited by this paper
• Oxidative stress and inflammation in iron‐overloaded patients with β‐thalassaemia or sickle cell disease

  2006cited by this paper
• Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy

  2006cited by this paper
• Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice.

  2006cited by this paper
• Iron absorption from soybean ferritin in nonanemic women.

  2006cited by this paper
• Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease.

  2006cited by this paper
• Activated neutrophil-mediated sickle red blood cell adhesion to lung vascular endothelium: role of phosphatidylserine-exposed sickle red blood cells.

  2006cited by this paper
• The effects of erythropoetic activity and iron burden on hepcidin expression in patients with thalassemia major.

  2006cited by this paper
• Identification of an intestinal heme transporter.

  2005cited by this paper
• Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial.

  2005cited by this paper
• GROWTH DIFFERENTIATION FACTOR-15/MACROPHAGE INHIBITORY CYTOKINE-1 INDUCTION AFTER KIDNEY AND LUNG INJURY

  2005cited by this paper
• Serum C-reactive protein parallels secretory phospholipase A2 in sickle cell disease patients with vasoocclusive crisis or acute chest syndrome.

  2005cited by this paper
• TNF, IFN-γ, and endotoxin increase expression of DMT1 in bronchial epithelial cells

  2005cited by this paper
• The iron-regulatory peptide hormone hepcidin: expression and cellular localization in the mammalian kidney.

  2005cited by this paper
• Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease.

  2005cited by this paper
• Regulation of hepcidin transcription by interleukin-1 and interleukin-6.

  2005cited by this paper
• Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 overexpression and down-regulated by hepcidin.

  2005cited by this paper
• Endothelial cell NADPH oxidase mediates the cerebral microvascular dysfunction in sickle cell transgenic mice

  2005cited by this paper
• TNF, IFN-gamma, and endotoxin increase expression of DMT1 in bronchial epithelial cells.

  2005cited by this paper
• Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization

  2004cited by this paper
• Iron chelation therapy in sickle-cell disease and other transfusion-dependent anemias.

  2004cited by this paper
• Identification of a human heme exporter that is essential for erythropoiesis.

  2004cited by this paper
• IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin.

  2004cited by this paper
• Oxidant-mediated impairment of nitric oxide signaling in sickle cell disease--mechanisms and consequences.

  2004cited by this paper
• Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients.

  2004cited by this paper
• Altered dietary iron intake is a strong modulator of renal DMT1 expression.

  2003cited by this paper
• Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein.

  2003cited by this paper
• Liver Ferritin Subunit Ratios in Neonatal Hemochromatosis

  2003cited by this paper
• Iron overload related to excessive vitamin C intake.

  2003cited by this paper
• JunB inhibits proliferation and transformation in B-lymphoid cells.

  2003cited by this paper
• Cytokine-mediated regulation of iron transport in human monocytic cells.

  2003cited by this paper
• Molecular and functional roles of duodenal cytochrome B (Dcytb) in iron metabolism.

  2002cited by this paper
• Secondary iron overload.

  2001cited by this paper
• Progression of iron overload in sickle cell disease.

  2001cited by this paper
• Nramp 2 (DCT1/DMT1) Expressed at the Plasma Membrane Transports Iron and Other Divalent Cations into a Calcein-accessible Cytoplasmic Pool*

  2000cited by this paper
• Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter

  2000cited by this paper
• Blockade of adhesion of sickle cells to endothelium by monoclonal antibodies.

  2000cited by this paper
• Characterization of Growth-Differentiation Factor 15, a Transforming Growth Factor β Superfamily Member Induced following Liver Injury

  2000cited by this paper
• Commentary on and reprint of Pauling L, Itano HA, Singer SJ, Wells IC, Sickle cell anemia, a molecular disease, in Science (1949) 110:543–548

  2000cited by this paper
• Reference distributions for the negative acute‐phase serum proteins, albumin, transferrin and transthyretin: A practical, simple and clinically relevant approach in a large cohort

  1999cited by this paper
• [Secondary iron overload].

  1998cited by this paper
• Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography.

  1998cited by this paper
• Membrane phospholipid asymmetry in human thalassemia.

  1998cited by this paper
• Cloning and characterization of a mammalian proton-coupled metal-ion transporter

  1997cited by this paper
• Ferritin translation by interleukin-6: the role of sequences upstream of the start codons of the heavy and light subunit genes

  1996cited by this paper
• Ferritin translation by interleukin-1and interleukin-6: the role of sequences upstream of the start codons of the heavy and light subunit genes.

  1996cited by this paper
• Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions.

  1995cited by this paper
• Erythropoietin: oxygen-dependent control of erythropoiesis and its failure in renal disease.

  1994cited by this paper
• Acute phase reactants and severity of homozygous sickle cell disease

  1993cited by this paper
• Hydroxyl radical formation by sickle erythrocyte membranes: role of pathologic iron deposits and cytoplasmic reducing agents.

  1991cited by this paper
• [Differences in the pattern of iron accumulation in primary and secondary hemochromatosis. Diagnostic importance and clinical consequences].

  1990cited by this paper
• Model of reticuloendothelial iron metabolism in humans: abnormal behavior in idiopathic hemochromatosis and in inflammation.

  1989cited by this paper
• Endoscopic and gastric acid studies in homozygous sickle cell disease and upper abdominal pain.

  1989cited by this paper
• Iron overload and iron chelation therapy in thalassaemia and sickle cell haemoglobinopathies.

  1987cited by this paper
• Compartmentalization of iron in sickle cell anemia--an autopsy study.

  1985cited by this paper
• Iron deficiency and sickle cell anemia.

  1983cited by this paper
• The diagnosis of iron deficiency anemia in sickle cell disease.

  1981cited by this paper
• Vitamin C and iron.

  1981cited by this paper
• Iron studies in patients with sickle cell disease.

  1981cited by this paper
• Iron burden in sickle cell anemia.

  1978cited by this paper
• Urinary iron in patients with sickle cell anamia.

  1975cited by this paper
• Iron metabolism, sickle cell disease, and response to cyanate.

  1975cited by this paper
• Studies on iron metabolism in sickle cell anaemia, sickle cell haemoglobin C disease, and haemoglobin C disease using a large volume liquid scintillation counter

  1970cited by this paper
• Urinary iron excretion and renal metabolism of hemoglobin in hemolytic diseases.

  1966cited by this paper
• Studies on congenital hemolytic syndromes, IV. Gastrointestinal absorption of iron.

  1962cited by this paper
• Studies on congenital hemolytic syndromes. III. Rates of destruction and production of erythrocytes in sickle cell anemia.

  1960cited by this paper
• Sickle cell anemia a molecular disease.

  1949cited by this paper
• ASH 50th Anniversary Reviews (34 articles)

  year unknowncited by this paper

• CB2 and TRPV1 receptors in inflammatory state of macrophages from sickle cell anemia pediatric/young adults

  2025cites this paper
• Dermatologic manifestations of hereditary hemochromatosis: A systematic review

  2024cites this paper
• Molecular Mechanisms of Hepatic Dysfunction in Sickle Cell Disease: Lessons From The Townes Mouse Model.

  2022cites this paper
• Deferiprone versus Deferoxamine in Sickle Cell Disease: Results Deferiprone versus Deferoxamine in Sickle Cell Disease: Results from a 5-year long-term Italian multi-center randomized clinical from a 5-year long-term Italian multi-center randomized clinical trial. trial.

  2022cites this paper
• Sleep in children with genetic disorders

  2021cites this paper
• Transient Elastography (TE) is a Useful Tool for Assessing the Response of Liver Iron Chelation in Sickle Cell Disease Patients

  2018cites this paper
• Influence of Hepcidin in the Development of Anemia

  2018cites this paper
• Blood Pressure of Children and Adolescents with Sickle Cell Anemia in Basra, Iraq

  2017cites this paper
• Impact of alloimmunization on transfusion-dependent patients

  2017cites this paper
• Double heterozygocity for hemoglobin C and beta thalassemia dominant: A rare case of thalassemia intermedia

  2017cites this paper
• Liver Iron Content (LIC) in Adults with Sickle Cell Disease (SCD): Correlation with Serum Ferritin and Liver Enzymes Concentrations in Trasfusion Dependent (TD-SCD) and Non-Transfusion Dependent (NT-SCD) Patients

  2017cites this paper
• Assessing cardiac and liver iron overload in chronically transfused patients with sickle cell disease

  2016cites this paper
• Comparative Analysis of Iron Homeostasis in Sub-Saharan African Children with Sickle Cell Disease and Their Unaffected Siblings

  2016cites this paper
• Hemopexin therapy reverts heme-induced proinflammatory phenotypic switching of macrophages in a mouse model of sickle cell disease.

  2016cites this paper
• Longitudinal MRI and Ferritin Monitoring of Iron Overload in Chronically Transfused and Chelated Children With Sickle Cell Anemia and Thalassemia Major

  2016cites this paper
• RED CELLS , IRON , AND ERYTHROPOIESIS Hemopexin therapy reverts heme-induced proin fl ammatory phenotypic switching of macrophages in a mouse model of sickle cell disease

  2016cites this paper
• Serum Ferritin and Severity Scores in Sickle Cell Disease Patients in Nnewi (South East Nigeria)

  2016cites this paper
• Iron, Inflammation, and Early Death in Adults With Sickle Cell Disease

  2015cites this paper
• Mechanisms of sickle cell alloimmunization.

  2015cites this paper
• EVALUATION OF IRON STATUS AMONG SUDANESE PATIENTS WITH SICKLE CELL DISEASE RECEIVING CHRONIC RED BLOOD CELL TRANSFUSION

  2015cites this paper
• Comparative Evaluation of Nephrotoxicity and Management by Macrophages of Intravenous Pharmaceutical Iron Formulations

  2015cites this paper
• Hemoglobinopathies in Pregnancy

  2015cites this paper
• Medical complications, resource utilization and costs in patients with myelofibrosis by frequency of blood transfusion and iron chelation therapy

  2015cites this paper
• Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease.

  2014cites this paper
• Iron Status of Multiple Transfused Sickle Cell Anaemia Patients Attending a Sickle Cell Clinic in Benin City, Nigeria

  2014cites this paper
• Deferiprone versus deferoxamine in sickle cell disease: results from a 5-year long-term Italian multi-center randomized clinical trial.

  2014cites this paper
• Profound Morphological Changes in the Erythrocytes and Fibrin Networks of Patients with Hemochromatosis or with Hyperferritinemia, and Their Normalization by Iron Chelators and Other Agents

  2014cites this paper
• H-ferritin ferroxidase induces cytoprotective pathways and inhibits microvascular stasis in transgenic sickle mice

  2014cites this paper
• Deferasirox for managing transfusional iron overload in people with sickle cell disease.

  2014cites this paper
• SOD2 deficiency in hematopoietic cells in mice results in reduced red blood cell deformability and increased heme degradation.

  2013cites this paper
• Age‐related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs

  2013cites this paper
• Safety And Efficacy Of 4 Years Of Deferasirox Treatment For Sickle Cell Disease Patients

  2013cites this paper
• The murine growth differentiation factor 15 is not essential for systemic iron homeostasis in phlebotomized mice

  2013cites this paper
• Beyond the Definitions of the Phenotypic Complications of Sickle Cell Disease: An Update on Management

  2012cites this paper
• Non-transferrin bound iron: a key role in iron overload and iron toxicity.

  2012cites this paper
• A Review of Sleep Concerns in Paediatric Sickle Cell Disease

  2012cites this paper
• The dangers of iron overload: Bring in the Iron Police

  2012influential citation
• Chelation treatment in sickle‐cell‐anaemia: much ado about nothing?

  2011cites this paper
• Advances in iron chelation: an update

  2011cites this paper
• Iron overload: what is the role of public health?

  2011cites this paper
• Iron in sickle‐cell disease: What have we learned over the years?

  2011cites this paper
• Periodic limb movements and disrupted sleep in children with sickle cell disease.

  2011cites this paper
• Growth differentiation factor 15 in patients with congenital dyserythropoietic anaemia (CDA) type II

  2011cites this paper
• PLMS AND DISRUPTED SLEEP IN CHILDREN WITH SICKLE CELL DISEASE Periodic Limb Movements and Disrupted Sleep in Children with Sickle Cell Disease and disrupted sleep in children

  2011cites this paper
• Long-term safety and efficacy of deferasirox (Exjade®) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease

  2011cites this paper
• Expression of an Innate Immune Element (Mouse Hepcidin-1) in Baculovirus Expression System and the Comparison of Its Function with Synthetic Human Hepcidin-25

  2011cites this paper
• Iron Overload in Sickle Cell Disease

  2010cites this paper
• Ferritin iron minerals are chelator targets, antioxidants, and coated, dietary iron

  2010cites this paper